The Vss value of digoxin increased in rats with non-alcoholic fatty liver disease owing to enhanced hepatic P-gp expression, leading to changes in digoxin pharmacokinetics [43]. The gene discussed is PGP; the disease is metabolic dysfunction-associated steatotic liver disease.